Livraison gratuite à partir de 300 francs
Plus de 30 ans d'expérience
Options de financement individuel
Certifié ISO 13485 depuis 1997
Axonlab Logo
  • Blog
  • Appareils & Instruments (547)
  • Réactifs & Chimiques (4'443)
  • Contrôles & Calibrateurs (181)
  • Consommables (2'444)
  • Accessoires (886)
  • Tests rapides (88)

Accès direct aux sections

  • Cabinet médical
  • Logiciel de laboratoire axonio
  • Logiciel de cabinet médical
  • Domaine des pharmacies
  • Diagnostic Snibe
  • Point-of-Care (POCT)

Antigen meets PCR: two methods, one goal – the right diagnosis at the right time

  • 5 Minutes à lire
  • Écrit par Axon Lab AG
  • Cabinet médical

Respiratory infections caused by influenza, RSV, SARS-CoV-2 and other pathogens often produce similar symptoms and are difficult to distinguish clinically. The COVID-19 pandemic has further highlighted the importance of fast and reliable diagnostic methods.

 

Before the pandemic: clinical assessment and targeted rapid tests

Before the COVID-19 pandemic, the diagnosis of respiratory infections in primary care was often based initially on clinical assessment.

In addition, point-of-care rapid tests were available for individual pathogens, such as influenza A/B, RSV or group A streptococci. They were easy to perform, relatively inexpensive and provided diagnostic guidance within a few minutes.

Their main limitation, however, was the limited range of detectable pathogens and, compared with molecular methods, an often lower sensitivity. Particularly at low pathogen loads, a negative antigen result could miss an existing infection.

For more sensitive molecular diagnostics, samples were typically sent to a central laboratory.

This created a classic trade-off:

A quick decision on site – or more sensitive diagnostics in the laboratory.

 

During the pandemic: PCR becomes the key molecular detection method

SARS-CoV-2 fundamentally changed the situation. PCR became established as an important method for the sensitive detection of SARS-CoV-2, while rapid antigen tests were widely used, particularly for screening and point-of-care applications, thanks to their ease of use and short test time.

The pandemic showed that speed alone is not always enough. At low viral loads, antigen tests can miss infections, whereas molecular tests offer higher sensitivity.

At the same time, it became clear that diagnostic results must be available reliably and quickly for clinical decision-making.

 

After the pandemic: molecular diagnostics comes to the patient

After the pandemic, molecular diagnostics remains an important part of respiratory diagnostics. A key development in this context is the miniaturisation and automation of molecular test methods.

Modern POCT PCR systems bring molecular diagnostics closer to where clinical decisions are made – for example in the emergency department, outpatient clinic, doctor’s practice or directly in the laboratory.

This makes it possible to combine the high sensitivity of molecular methods with a short turnaround time.

As a result, the diagnostic workflow is changing:

The sample no longer has to go to the laboratory – molecular diagnostics is increasingly coming to the sample.

 

From single-pathogen testing to multiplex diagnostics

Modern multiplex PCR systems can simultaneously detect and differentiate several relevant respiratory pathogens from a single sample, for example:

  • Influenza A/B
  • RSV
  • SARS-CoV-2
  • Mycoplasma pneumoniae
  • Bordetella pertussis

This shifts the key question

from “Which pathogen should I test for?”
to “Which pathogen is causing this respiratory syndrome?”

 

Rapid antigen tests and POCT PCR – different strengths

Rapid antigen tests and POCT PCR are therefore not necessarily competitors. Both methods have their place and address different diagnostic requirements.

The rapid antigen test remains attractive where ease of use, fast availability and low costs are the priority.

POCT PCR offers advantages when a fast and at the same time highly sensitive result is relevant for a clinical or organisational decision – especially when several possible pathogens need to be differentiated.

 

Conclusion

The development of respiratory diagnostics can be described, in simplified terms, as a transition:

from “fast on site or sensitive in the laboratory”
to “fast and sensitive at the point of clinical decision-making”

 

The aim is not to replace antigen tests with PCR. Rather, diagnostic options are evolving: from clinical assessment and targeted single tests, through centralised molecular diagnostics, to automated, syndromic multiplex PCR directly at the point of care.

The combination of multiplexing, automation, high sensitivity and short turnaround time is therefore a key trend in modern respiratory diagnostics.

Publications les plus consultées
  • Instructions pour le téléchargement des fiches de contrôle de qualité
    Jeanette Fehlmann
  • La CRP, un biomarqueur des infections virales et bactériennes
  • Mesure la CRP avec le Microsemi CRP & Microsemi CRP LC-767
    Jeanette Fehlmann
Catégories de blogs
  • Entreprise
  • Hôpitaux & Laboratoires
  • Pharmacie
  • Life Science
  • Cabinet médical
  • Diagnostic moléculaire
  • Microbiologie

Liens

  • À propos de nous
  • Ce que nous faisons
  • Nous nous présentons
  • Responsabilité sociale
  • Offres d'emploi
  • Events
  • Blog
  • Téléchargements
  • Support & Service d’assistance
  • CGV
  • Politique de confidentialité
  • Mentions légales
  • Conditions d'envoi et de livraison
  • Certification
  • FAQ
  • Startup Lab Program

Accéder au centre d’assistance

  • 0848 00 29 66
  • Lundi - vendredi
  • 8:00 - 12:00 heures | 13:00 - 17:00 heures
  • Accéder au centre d’assistance

Nous contacter

  • Axon Lab AG
  • En Budron A5
  • 1052 Le Mont-sur-Lausanne
  • +41 21 651 71 50
  • info_f@axonlab.ch

Newsletter

Tous les prix sont indiqués en CHF, hors TVA et hors frais d'expédition, sauf indication contraire.